Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Benjamin C. Ede"'
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Dexamethasone (Dex) is a highly insoluble front-line drug used in cancer therapy. Data from clinical trials indicates that the pharmacokinetics of Dex vary considerably between patients and prolonging drug exposure rather than increasing abs
Externí odkaz:
https://doaj.org/article/7b565fee84e34ae2a46e1d888530d47a
Publikováno v:
Haematologica, Vol 103, Iss 9 (2018)
Current therapies for childhood T-cell acute lymphoblastic leukemia have increased survival rates to above 85% in developed countries. Unfortunately, some patients fail to respond to therapy and many suffer from serious side effects, highlighting the
Externí odkaz:
https://doaj.org/article/79a9d5c1dc4147e48268604146e42953
Autor:
Allison Blair, John Moppett, Benjamin C Ede, Paraskevi Diamanti, Robert A. Uger, Charlotte V. Cox
Publikováno v:
Blood Adv
Diamanti, P, Cox, C V, Blair, A, Ede, B & Moppett, J P 2021, ' Targeting pediatric leukemia propagating cells using anti-CD200 antibody therapy. ', Blood Advances, vol. 5, no. 18, pp. 3694–3708 . https://doi.org/10.1182/bloodadvances.2020003534
Diamanti, P, Cox, C V, Blair, A, Ede, B & Moppett, J P 2021, ' Targeting pediatric leukemia propagating cells using anti-CD200 antibody therapy. ', Blood Advances, vol. 5, no. 18, pp. 3694–3708 . https://doi.org/10.1182/bloodadvances.2020003534
Treating refractory pediatric acute lymphoblastic leukemia (ALL) remains a challenge despite impressive remission rates (>90%) achieved in the last decade. The use of innovative immunotherapeutic approaches such as anti-CD19 chimeric antigen receptor
Autor:
Phoebe E I Dace, John Moppett, Benjamin C Ede, Paraskevi Diamanti, William J Barendt, Jeremy Hancock, Allison Blair, Charlotte V. Cox
Publikováno v:
British Journal of Haematology
Diamanti, P, Ede, B C, Dace, P E I, J Barendt, W, Cox, C V, Hancock, J P, Moppett, J P & Blair, A 2020, ' Investigating the response of paediatric leukaemia propagating cells to BCL-2 inhibitors ', British Journal of Haematology . https://doi.org/10.1111/bjh.16773
Diamanti, P, Ede, B C, Dace, P E I, J Barendt, W, Cox, C V, Hancock, J P, Moppett, J P & Blair, A 2020, ' Investigating the response of paediatric leukaemia propagating cells to BCL-2 inhibitors ', British Journal of Haematology . https://doi.org/10.1111/bjh.16773
Summary Relapse of paediatric acute lymphoblastic leukaemia (ALL) may occur due to persistence of resistant cells with leukaemia‐propagating ability (LPC). In leukaemia, the balance of B‐cell lymphoma‐2 (BCL‐2) family proteins is disrupted, p
Publikováno v:
Ede, B, Diamanti, P, Williams, D S & Blair, A 2021, ' Non-toxic polymer nanovectors for improved delivery of dexamethasone. ', Scientific Reports, vol. 11, 17263 (2021) . https://doi.org/10.1038/s41598-021-96797-4
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Scientific Reports
Dexamethasone (Dex) is a highly insoluble front-line drug used in cancer therapy. Data from clinical trials indicates that the pharmacokinetics of Dex vary considerably between patients and prolonging drug exposure rather than increasing absolute dos
Publikováno v:
Ede, B C, Asmaro, R R, Moppett, J P, Diamanti, P & Blair, A 2018, ' Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide ', Haematologica, vol. 103, no. 9, pp. 1493-1501 . https://doi.org/10.3324/haematol.2017.186700
Haematologica
Haematologica
Current therapies for childhood T-cell acute lymphoblastic leukemia have increased survival rates to above 85% in developed C countries. Unfortunately, some patients fail to respond to therapy and many suffer from serious side effects, highlighting t
Publikováno v:
Blood. 136:9-9
Drugs used to treat childhood acute lymphoblastic leukemia (ALL), both clinically and experimentally, are often highly insoluble making drug delivery inefficient due to precipitation and poor distribution. Toxicity is also a major issue owing to the
Autor:
Benjamin C Ede, David S. Williams, Roxane Ridolfo, Jan C. M. van Hest, Paraskevi Diamanti, Adam W. Perriman, Allison Blair, Paul B. White
Publikováno v:
Small, 14(32):1703774. Wiley-VCH Verlag
Small, 14, 1-10
Small, 14, 32, pp. 1-10
Small
Ridolfo, R, Ede, B C, Diamanti, P, White, P B, Perriman, A W, van Hest, J C M, Blair, A & Williams, D S 2018, ' Biodegradable, Drug-Loaded Nanovectors via Direct Hydration as a New Platform for Cancer Therapeutics ', Small, vol. 14, no. 32, 1703774 . https://doi.org/10.1002/smll.201703774
Small, 14, 1-10
Small, 14, 32, pp. 1-10
Small
Ridolfo, R, Ede, B C, Diamanti, P, White, P B, Perriman, A W, van Hest, J C M, Blair, A & Williams, D S 2018, ' Biodegradable, Drug-Loaded Nanovectors via Direct Hydration as a New Platform for Cancer Therapeutics ', Small, vol. 14, no. 32, 1703774 . https://doi.org/10.1002/smll.201703774
The stabilization and transport of low-solubility drugs, by encapsulation in nanoscopic delivery vectors (nanovectors), is a key paradigm in nanomedicine. However, the problems of carrier toxicity, specificity, and producibility create a bottleneck i
Autor:
Andrew Collins, Gabriella Morrison, Robert C. Deller, Adam W. Perriman, James Reilly, Paraskevi Diamanti, Robert M. Richardson, Kristian Le Vay, Allison Blair, Benjamin C Ede
Publikováno v:
Deller, R C, Diamanti, P, Morrison, G, Reilly, J, Ede, B C, Richardson, R, Le Vay, K, Collins, A M, Blair, A & Perriman, A W 2017, ' Functionalized triblock copolymer vectors for the treatment of acute lymphoblastic leukemia ', Molecular Pharmaceutics, vol. 14, no. 3, pp. 722-732 . https://doi.org/10.1021/acs.molpharmaceut.6b01008
The chemotherapeutic Parthenolide is an exciting new candidate for the treatment of acute lymphoblastic leukemia, but like many other small-molecule drugs, it has low aqueous solubility. As a consequence, Parthenolide can only be administered clinica
Publikováno v:
Blood. 132:4033-4033
CD200 is an immunomodulatory molecule overexpressed in childhood B cell precursor (BCP) acute lymphoblastic leukaemia (ALL). In minimal residual disease (MRD) low risk cases it has been shown that only CD200+ cells could engraft and self-renew in NOD